Sofwave Medical in the first quarter: profitability held, but cash still waits for deeper utilization

Company Overview

Sofwave Medical entered 2026 in a different position from a year earlier. It is no longer only a medical device company selling ultrasound consoles into aesthetic medicine. It is starting to look like a utilization platform: a device sold to a physician, repeat treatments, and usage fees collected on pulses over the system’s life. In the first quarter, revenue rose to $24.4 million, usage fee revenue reached $11.0 million, and net income was $1.3 million. That strengthens the shift from a sales story to a utilization story.

But the picture is still not clean. Accounting profit is positive, yet operating cash flow was still negative by $0.7 million. Profitability held outside the seasonally strong fourth quarter, but it did not repeat the fourth-quarter peak. Usage fees are already above 40% of revenue, but they are not a locked subscription. They depend on actual treatment volume. The body platform, which is supposed to expand the company’s market beyond facial and skin tightening, still does not receive a separate revenue breakdown. The active bottleneck is clear: proving that deeper use of the installed base and the body platform turns into recurring cash, not only into revenue that keeps requiring inventory, marketing and working capital.

This article naturally continues the prior coverage. In the previous annual analysis, the open question was whether the fourth quarter of 2025 was an unusually strong seasonal jump or the start of a new profitability base. The first quarter does not replicate Q4, which is expected for a company whose capital equipment sales tend to be stronger at year end. Still, it no longer resembles the first quarter of 2025: revenue grew 46%, a $1.0 million operating loss became $1.6 million of operating income, and the company ended the quarter with about $35.1 million of cash including a restricted deposit.

Sofwave’s economic map is compact, but each layer tells a different story:

This chart matters because it separates two very different readings of the growth. System sales rose about 39%, which shows that the installed base is still expanding. Usage fees rose faster, by about 56%, and that is the number that carries the platform story. The more growth comes from systems already working at customers, the more stable the company’s economics can become. If growth reverts mainly to new equipment sales, the story stays more exposed to physician and distributor capital spending cycles.

Events And Triggers

The first quarter showed that profitability was not only a year-end event. Revenue reached $24.4 million and operating income was $1.6 million, compared with an operating loss in the same quarter last year. This is an important transition point. A medical device company in commercialization mode can show attractive revenue and still burn cash and lose money. Here, profitability already appears in a less favorable seasonal quarter.

The right comparison is not only against Q4. The fourth quarter of 2025 was unusually strong, with $28.9 million of revenue and $4.2 million of operating income. The first quarter of 2026 was about 16% lower in revenue than Q4, but 46% higher than Q1 2025. In a company that also sells capital equipment, Q4 tends to benefit from U.S. year-end budget and tax purchasing behavior, while Q1 is also affected by Chinese New Year and Asia-linked supply chain components. The current quarter is not weak only because it is not Q4. It does, however, set a clear hurdle: Q2 and Q4 need to show that the new base is not only a year-end effect.

Usage fees keep closing the gap between device sale and platform economics. The company estimates that about 865,000 treatments have been performed since commercialization, and usage fees reached $11.0 million in the quarter. In the follow-up analysis on usage fees, the key point was that this revenue recurs as long as physicians keep using the device, but it is not a contractual subscription with forward commitments. The first quarter improves the positive side of that equation: usage grew faster than system sales. It still leaves open the quality of collections and working capital.

The body platform is advancing, but it still lacks its own proof line. Pure Impact VIP received FDA clearance as a standalone product in 2025, and Lift HD has a clearer path on the existing console. In the first quarter, the company recorded an $80,000 royalty liability related to Pure Impact sales, after $217,000 of such royalties in 2025. That is evidence of commercial activity, but not enough to measure adoption. There is still no disclosure on body revenue, units, utilization or repeat customer behavior. In the body-platform follow-up, the key issue was the difference between a product that expands the market on paper and one that already changes the revenue trajectory. The first quarter did not close that gap.

The U.S. process is a market trigger, not an operating trigger. The board authorized management to evaluate a confidential draft F-1 filing with the SEC, and the shareholders’ meeting approved corporate steps that are conditional on a U.S. IPO or listing. This could improve access to U.S. investors and connect the company to the market where much of its commercial story already sits. At this stage, though, there are no offering terms, no price, no size and no certainty. It is an option that can raise market interest, not business proof that replaces revenue, cash flow or product adoption.

Efficiency, Profitability And Competition

The first quarter shows real operating leverage: revenue rose 46%, while R&D increased 22%, sales and marketing rose 25%, and G&A rose 7%. When revenue grows faster than expenses, the model begins to work in shareholders’ favor. That is the difference between a company that needs growth merely to cover its cost base and a company where each additional layer of use can leave more operating profit.

Still, the improvement is not uniform across the income statement. Gross margin fell from 76.3% to 75.0%, because cost of sales grew faster than revenue. The decline is not dramatic, but it is a reminder that this is not a pure software business. There are components, inventory, shipping, service, warranty and royalties. In 2025, U.S. tariffs were estimated to have reduced gross margin by about 0.5 percentage points, and in the first quarter of 2026 the company is already subject to a 10% tariff on goods imported into the U.S. Gross margin remains high, but it is not immune to a harsher trade environment.

Growth came from more than the U.S.

The U.S. remains central, and the company sells there directly through its own sales force. But in the first quarter, the sharper growth came from East Asia and EMEA. U.S. revenue rose to $10.8 million, up 20% year over year. East Asia revenue rose to $9.1 million, up 79%, and EMEA reached $3.2 million, up 73%. That gives Sofwave better geographic spread, but it also increases dependence on distributors, supply chains and local market conditions.

The company still reports one operating segment, so the more useful breakdown is economic rather than segmental: new systems, repeat usage and body. New systems add installed base. Usage fees test whether that installed base is alive. Body products are supposed to increase the possible treatment universe on the same console or with a complementary product. If all three layers move together, the relatively fixed parts of development, sales and infrastructure can be spread over higher revenue. If only system sales move, the company remains more exposed to equipment purchasing cycles.

FDA clearances do not remove competition

Sofwave operates in a crowded medical aesthetics market against larger and better-known companies. FDA clearances, clinical studies and a growing installed base help build trust, but they do not block competition. Physicians can choose among technologies, brands and economic models. The company’s advantage needs to come less from the clearance itself and more from physician ROI: treatment pricing, number of treatments, patient satisfaction, and whether the customer returns to buy more pulses. That is why usage fees are a higher-quality metric than the number of systems sold on its own.

Cash Flow, Debt And Capital Structure

The balance sheet is more comfortable than the cash-flow picture. Sofwave has no bank debt, and cash including the restricted deposit was $35.1 million at the end of March 2026, almost unchanged from the end of 2025. Equity rose to $35.0 million, and current liabilities declined from $22.3 million to $21.6 million. This is not a company entering the next quarter under immediate financing pressure.

But the all-in cash picture is less strong than net income. Net income was $1.3 million, while operating cash flow was negative by $0.7 million. The gap came mainly from working capital: inventory rose to $5.5 million, trade receivables rose to $7.9 million, other receivables rose, and accrued liabilities declined mainly because year-end bonus accruals were paid. This is not necessarily a problem, but it is a test. A company growing utilization and sales often needs to finance inventory, demo systems and customer credit before cash arrives.

This is the all-in cash flexibility view, not normalized cash generation. It asks what happened after actual cash uses during the quarter: operations, investing, leases, option exercises and FX. On that basis, the cash balance barely moved. But if the goal is to test recurring earnings quality, operating cash flow is the more important figure, and it was still negative this quarter.

Two points reduce balance-sheet risk. First, there is no bank debt creating covenants or near-term refinancing needs. Second, option exercises brought in $0.6 million and reduced the cash decline. The second point also reminds investors that part of a growth company’s financial flexibility can come from equity and options, not only operations. If the company later proceeds with a U.S. transaction, the market will assess not only the listing itself but also its economic price: amount raised, dilution, cash use and whether it accelerates sales or only builds the cash balance.

Outlook

Four non-obvious findings should frame the next few quarters. First, the first quarter is very strong versus last year, but below Q4. That means 2026 is not measured only by whether the company is profitable, but by whether it can hold a profitability base when there is no year-end tailwind. Second, usage fees already act like a core engine, but their recognition depends on actual use and payment, so collections and customer behavior are as important as revenue growth. Third, the body platform has regulatory and commercial framing, but still lacks a measurement line showing that it changes the company profile. Fourth, the cash balance is strong, but the quarter still did not generate positive operating cash flow.

2026 currently looks like a proof year, not a harvest year. The company needs to show that the model appearing in the numbers can repeat in non-Q4 quarters, and that usage fees remain above 40% of revenue without increasing working capital at a pace that absorbs cash. If Q2 and Q4 are strong, and if Q3 does not revert to a severe seasonal slowdown, the market will have a better basis for treating the company as one that sells both systems and recurring use. If growth continues to come mainly from new systems, the platform story will be less convincing.

What the next few quarters need to prove

Management continues to frame the market around demand for non-invasive aesthetic procedures, short downtime and natural-looking results. It also presents the GLP-1 environment as a potential demand driver for body treatments, because weight loss can leave skin laxity or create demand for muscle tone. That is an interesting framework, but not yet a number. Until product-specific sales and usage data are disclosed for the body platform, the market should treat it as a potential growth engine, not a proven contribution.

The point the market may miss is that first-quarter profitability was not just cost cutting. Expenses are still rising, but they are rising more slowly than revenue. That is a good sign for a company selling a high gross margin product. The same mechanism can also work in reverse if revenue slows: a U.S. sales force of 42 employees, direct U.K. operations, distributors in about 50 countries, clinical work, regulation and service are not cost layers that can be reduced quickly without hurting growth. Quarterly profitability still needs a track record.

Risks

The first risk is growth quality. High usage fees are positive, but they depend on treatment volume and actual payment. If physicians buy systems but use them less than expected, recurring revenue weakens. If the company needs to offer more credit or easier terms to expand the installed base, growth can look strong in the income statement while weighing on cash flow.

The second risk is competition. Sofwave operates in a market where physicians have many alternatives, and some competitors are far larger. Regulatory clearance does not remove the need to convince physicians that the system is economically attractive. If customer acquisition costs rise or treatment pricing declines, usage fees can continue to grow while leaving less profit.

The third risk is supply chain and tariffs. The company imports components from Asia-linked suppliers and sells a meaningful part of its activity into the U.S. The current 10% tariff on goods imported into the U.S. is already identified as a risk whose future path is uncertain. In 2025, the gross margin effect was limited, but if tariff rates change or shipping and service costs rise, the 75% margin could erode.

The fourth risk is currency. The functional currency is the U.S. dollar, but some expenses in Israel are paid in shekels. A stronger shekel against the dollar increases reported dollar expenses. This is not the main risk in the current quarter, but sharp currency moves could distort the relationship between operating performance and reported profit.

The fifth risk is dilution and access to capital. The company has a strong cash balance and no bank debt, but it remains a growth company funding development, regulation, marketing and commercial infrastructure. A U.S. listing or offering process could open access to a deeper market, but it could also create dilution or higher expectation pressure. Such a move is positive only if it connects new capital to faster utilization and sales, not merely to a larger cash balance.

The sixth risk is limited body-platform disclosure. Pure Impact VIP and Lift HD are important for the forward story, but numerical disclosure is still thin. An $80,000 royalty liability in the quarter shows Pure Impact sales, not adoption depth, treatment volume or product profitability. Without usage data, it is hard to separate real market expansion from a launch that is still small relative to the core face and skin business.

Conclusions

Sofwave opened 2026 with a quarter that strengthens the platform story, but does not close it. Revenue grew quickly, usage fees are already material, and profitability appeared in a quarter that was not Q4. The key constraint has moved from “is there demand” to a more precise question: whether that demand generates operating cash flow, repeat usage and measurable contribution from the body platform.

The one-sentence read is this: Sofwave has already shown it can be profitable, and now it needs to show that profit returns in cash and deeper system utilization.

Compared with the prior read, the first quarter reduces the concern that 2025 profitability was mainly a year-end event. It does not close the questions around cash conversion, collection quality, or the economic contribution of Pure Impact and Lift HD. The strongest counter-thesis is that much of the improvement still depends on expanding system sales and heavy marketing, while usage fees are not a locked subscription and the body platform still lacks enough numerical disclosure to justify a full risk-profile change.

What could change the market’s interpretation over the short to medium term? A strong second quarter with usage fees above 40% of revenue and positive operating cash flow would shorten the path toward viewing the company as having higher-quality revenue. A decline in usage fees, another increase in inventory or receivables, or a U.S. transaction with dilution that is not tied to faster operations would return the debate to growth quality. The business significance is clear: Sofwave is no longer only a young medical device story. It is now measured by its ability to turn installed base into utilization, utilization into profit, and profit into cash.